Reference
[1] Brodsky R A. How I Treat Paroxysmal Nocturnal Hemoglobinuria[J]. Blood, 2021, 137(10): 1304–1309. DOI: 10.1182/blood.2019003812
[2] Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review[J]. European Journal of Haematology, 2015, 95(3): 190–198. DOI: 10.1111/ejh.12543
[3] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet (London, England), 2020, 395(10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5
[4] Aleem A, Akbar Samad A B, Slenker A K. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19) [A]. In: StatPearls[M]. Treasure Island (FL): StatPearls Publishing, 2022.
[5] Afzali B, Noris M, Lambrecht B N, et al. The state of complement in COVID-19[J]. Nature Reviews. Immunology, 2022, 22(2): 77–84. DOI: 10.1038/s41577-021-00665-1
[6] Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact[J]. Kidney International, 2020, 98(2): 314–322. DOI: 10.1016/j.kint.2020.05.013
[7] A H, N H, J B. COVID-19 infection presenting as paroxysmal nocturnal hemoglobinuria[J]. Clinical case reports, Clin Case Rep, 2021, 9(8). DOI: 10.1002/ccr3.4636
[8] A G, T C, P B, et al. Severe COVID-19 infection in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab therapy[J]. Leukemia & lymphoma, Leuk Lymphoma, 2021, 62(6). DOI: 10.1080/10428194.2020.1869963
[9] Sokol J, Nehaj F, Mokan M, et al. COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria[J]. Medicine, 2021, 100(20): e25456. DOI: 10.1097/MD.0000000000025456
[10] Shikdar S, Borogovac A, Mohamad E, et al. COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab[J]. Thrombosis Journal, 2021, 19: 75. DOI: 10.1186/s12959-021-00330-6
[11] Araten D J, Belmont H M, Schaefer-Cutillo J, et al. Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders[J]. The American Journal of Case Reports, 2020, 21: e927418-1-e927418-4. DOI: 10.12659/AJCR.927418
[12] Pike A, Muus P, Munir T, et al. COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience[J]. British Journal of Haematology, 2020, 191(1): e1–e4. DOI: 10.1111/bjh.17097
[13] Barcellini W, Fattizzo B, Giannotta J A, et al. COVID‐19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey[J]. British Journal of Haematology, 2021, 194(5): 854–856. DOI: 10.1111/bjh.17558
[14] Kulasekararaj A G, Lazana I, Large J, et al. Terminal complement inhibition dampens the inflammation during COVID‐19[J]. British Journal of Haematology, 2020, 190(3): e141–e143. DOI: 10.1111/bjh.16916
[15] Schüller H, Klein F, Lübbert M, et al. Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report[J]. Annals of Hematology, 2021, 100(3): 841–842. DOI: 10.1007/s00277-020-04318-6
[16] Pravdic Z, Mitrovic M, Bogdanovic A, et al. COVID-19 Presented with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal Haemoglobinuria[J]. Hämostaseologie, Georg Thieme Verlag KG, 2021, 41(5): 397–399. DOI: 10.1055/a-1554-6432
[17] Iannuzzi A, Parrella A, De Ritis F, et al. Pancytopenia in a Case of Aplastic Anaemia/Paroxysmal Nocturnal Haemoglobinuria Unmasked by SARS-CoV-2 Infection: A Case Report[J]. Medicina, 2022, 58(9): 1282. DOI: 10.3390/medicina58091282
[18] Barcellini W, Fattizzo B, Quattrocchi L, et al; COVID-19 Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy. Blood 2020; 136 (Supplement 1): 36–37. DOI: https://doi.org/10.1182/blood-2020-138721
[19] Schrezenmeier H, Röth A, Araten D J, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry[J]. Annals of Hematology, 2020, 99(7): 1505–1514. DOI: 10.1007/s00277-020-04052-z
[20] Moore J B, June C H. Cytokine release syndrome in severe COVID-19[J]. Science, American Association for the Advancement of Science, 2020, 368(6490): 473–474. DOI: 10.1126/science.abb8925
[21] Passoni R, Lordani T V A, Peres L A B, et al. Occurrence of acute kidney injury in adult patients hospitalized with COVID-19: A systematic review and meta-analysis[J]. Nefrologia, 2022, 42(4): 404–414. DOI: 10.1016/j.nefroe.2022.11.005
[22] Clark D A, Butler S A, Braren V, et al. The kidneys in paroxysmal nocturnal hemoglobinuria[J]. Blood, 1981, 57(1): 83–89. DOI: 10.1182/blood.V57.1.83.83
[23] Risitano A M, Peffault de Latour R. How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future[J]. British Journal of Haematology, 2022, 196(2): 288–303. DOI: 10.1111/bjh.17753
[24] Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria[J]. American Journal of Hematology, 2010, 85(8): 553–559. DOI: 10.1002/ajh.21757
[25] Brodsky R A, Young N S, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria[J]. Blood, 2008, 111(4): 1840–1847. DOI: 10.1182/blood-2007-06-094136
[26] Hillmen P, Muus P, Röth A, et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria - Hillmen - 2013 - British Journal of Haematology - Wiley Online Library[J]. British Journal of Haematology, 2013, 162(1): 62–73. DOI: 10.1111/bjh.12347
[27] Hillmen P, Hall C, Marsh J C W, et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria[J]. New England Journal of Medicine, Massachusetts Medical Society, 2004, 350(6): 552–559. DOI: 10.1056/NEJMoa031688
[28] Di Franco S, Alfieri A, Petrou S, et al. Current status of COVID-19 treatment: An opinion review[J]. World Journal of Virology, 2020, 9(3): 27–37. DOI: 10.5501/wjv.v9.i3.27
[29] Wang R, Xiao H, Guo R, et al. The role of C5a in acute lung injury induced by highly pathogenic viral infections[J]. Emerging Microbes & Infections, 2015, 4(5): e28. DOI: 10.1038/emi.2015.28
[30] Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study[J]. EClinicalMedicine, 2020, 28: 100590. DOI: 10.1016/j.eclinm.2020.100590
[31] F D, Fg N, G P, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience[J]. European review for medical and pharmacological sciences, Eur Rev Med Pharmacol Sci, 2020, 24(7). DOI: 10.26355/eurrev_202004_20875